H.C. Wainwright placed its rating on Cidara Therapeutics under review after the company entered into an agreement with Janssen Pharmaceuticals to reacquire the exclusive global development and commercial rights to CD388. The firm regards the reacquisition of CD388 and the divestment of rezafungin as two transactions that both serve to enable Cidara to focus exclusively on its Cloudbreak DFC platform, spearheaded by CD388. The rating is under view pending the release of further financial details.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics Refocuses Strategy with Asset Sale
- Cidara Therapeutics: Strategic Partnerships and Governance Changes
- Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
- Cidara Therapeutics’ Restatement Woes: Costs, Distractions, and Investor Confidence on the Line
- Cidara Therapeutics trading halted, news pending
